Why Arrowhead Pharmaceuticals, Inc. (ARWR) stock moved
Arrowhead Pharmaceuticals, Inc. (ARWR) shares climbed 19.0% to $88.70 as of July 22, 2026, a sharp gain from the prior close of $74.52. BestStocks flagged the session as a major change for ARWR. Below, we break down what changed for ARWR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ARWR climbed 19.0% to $88.70
ARWR climbed 19.0% in its latest session, moving from $74.52 to $88.70.
What it means for Arrowhead Pharmaceuticals, Inc. investors
For Arrowhead Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Strong 19.0% price move with conviction; Volume 3.3x average — institutional conviction. Weighing against that: Arrowhead Pharmaceuticals, Inc. (ARWR) moved -3.57% from $74.30 to $71.65 on 2026-07-20; Arrowhead Pharmaceuticals, Inc. (ARWR) moved -9.05% from $84.00 to $76.40 on 2026-07-10. Wall Street's consensus price target sits at $88.00, implying -0.8% downside from $88.70. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 13 days out, the next report is the most likely near-term test of the move.
ARWR price reaction
ARWR last traded at $88.70, up $14.18 (+19.03%) from the previous close of $74.52. The session traded on 3.3× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $71.38 and $88.70, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Arrowhead Pharmaceuticals, Inc. (ARWR)
The consensus analyst price target on Arrowhead Pharmaceuticals, Inc. (ARWR) is $88.00, 0.8% below the recent $88.70. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ARWR line up.
The bullish case
- The Street's most bullish target is $115.00 (+29.7%).
- Strong 19.0% price move with conviction.
- Volume 3.3x average — institutional conviction.
- Arrowhead Pharmaceuticals, Inc. (ARWR) moved +4.01% from $71.65 to $74.52 on 2026-07-21.
The bearish case
- The consensus analyst price target of $88.00 sits 0.8% below the recent $88.70, so the average target sees limited room to run.
- The most bearish analyst target is $46.00 (-48.1%).
- Arrowhead Pharmaceuticals, Inc. (ARWR) moved -3.57% from $74.30 to $71.65 on 2026-07-20.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ARWR
Frequently asked questions about ARWR
Why did Arrowhead Pharmaceuticals, Inc. (ARWR) stock move?
ARWR climbed 19.0% to $88.70. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ARWR stock rise?
ARWR gained 19.03% ($14.18) versus the prior close of $74.52, last trading at $88.70 on 3.3× average volume.
When is Arrowhead Pharmaceuticals, Inc.'s next earnings date?
ARWR's next earnings report is estimated for 2026-08-04 — about 13 days away.
What is the analyst price target for ARWR?
The consensus analyst price target for ARWR is $88.00, about 0.8% below the current $88.70. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks ARWR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ARWR-specific materiality thresholds, triggering an evidence check. It draws on 13 tracked change events for ARWR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.